WESTBOROUGH, Mass.,
March 14, 2014 /PRNewswire/
-- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a
biotechnology company focused on discovering, developing and
commercializing innovative therapies addressing major unmet medical
needs using RNA-targeted technologies, today announced
upcoming presentations at the 6th Ocular Diseases and Drug
Development Conference, the 72nd Annual Meeting of the
American Academy of Dermatology ("AAD") and the Keystone Symposia
Meeting, Fibrosis: From Bench to Bedside.
6th Ocular Diseases and Drug Development Conference
On Thursday, March 20, 2014 at
10:55 a.m. PDT, Dr. Geert Cauwenbergh, President and CEO of RXi
Pharmaceuticals will be presenting an overview on the potential of
RNAi therapy in ocular disease. The Ocular Diseases and Drug
Discovery Conference promotes the discovery of ocular disease drug
development by bringing together leading scientists, researchers
and experts to discuss and collaborate on the latest research and
development, safety assessment, regulatory issues and drugs in
development for combating and curing ocular diseases, such as
age-related macular degeneration (AMD), diabetic retinopathy,
glaucoma, DME, uveitis and other ocular diseases. This
conference will take place March 20-21,
2014 in San Diego,
CA. Dr. Cauwenbergh's presentation will be available on the
Company's website.
72nd Annual Meeting of the American Academy of
Dermatology
The American Academy of Dermatology supports the
highest-quality patient care by developing and presenting
information that enhances continuing education in dermatology. AAD
meetings offer the latest on the diagnosis, prevention, and
treatment of dermatologic disease from the foremost experts in the
field. RXi's senior management team members will be
presenting three poster presentations on March 22, 2014. Poster 8326 "Reduction of
Connective Tissue Growth Factor (CTGF) by an RNA Interference
(RNAi) Mechanism as a Potential Treatment for Fibrotic Skin
Indications" will be presented by Dr. Pamela Pavco, RXi's Chief Development Officer at
4:10 p.m. MDT. Poster 8225
"RXI-109 Reduces a Key Component of Dermal Scarring, Connective
Tissue Growth Factor (CTGF) mRNA, in a Multi-dose Phase 1 Clinical
Trial" will be presented by Dr. Lyn
Libertine, Vice President Medical Affairs and Safety
Assessment for RXi, at 4:15 p.m.
MDT. Lastly, Poster 8214 "The RNAi Compound RXI-109
Reduces Connective Tissue Growth Factor (CTGF), a Key Component of
Dermal Scarring, at Incision Sites in a First-in-Human Phase 1
Clinical Trial" will be presented by Dr. Pavco at 4:25 p.m. MDT. All three posters will be
available on the Company's website.
Keystone Symposia Meeting, Fibrosis: From Bench to
Bedside
RXi's Manager of Platform Technology, Dr. James Cardia will present a poster titled
"Reduction of Connective Tissue Growth Factor (CTGF) by an RNA
Interference (RNAi) Mechanism as a Potential Treatment for Fibrotic
Skin Indications" on March 26, 2014
from 7:30-10:00 p.m. MDT. The
mission of the Keystone Symposia is to serve as a catalyst for the
advancement of biomedical and life sciences by connecting
scientists within and across disciplines at conferences and
workshops held at venues that create an environment conducive to
information exchange, a generation of new ideas and acceleration of
applications that benefit society. This Fibrosis Symposia brings
together researchers, with an interest in fibrosis, aiming to
bridge the gap between basic research and clinical findings and
pharmaceutical development and will take place March 23‑28, 2014,
at the Keystone Resort in Keystone, Colorado. Dr. Cardia's
presentation will be available on the Company's website.
About RXI-109
RXi Pharmaceuticals' first clinical program involves RXI‑109, a
self-delivering RNAi compound (sd‑rxRNA®) developed for the
reduction of dermal scarring. RXI‑109 is designed to reduce the
expression of connective tissue growth factor ("CTGF"), a critical
regulator of biological pathways involved in fibrosis, including
scar formation in the skin. The first clinical trials with RXI‑109
showed excellent safety and tolerability with ascending single and
multiple doses, as well as dose dependent effects on the CTGF
protein and on the mRNA that controls production of this
protein.
RXi's sd‑rxRNA oligonucleotides are designed for therapeutic use
and have drug-like properties, such as high potency, target
specificity, serum stability, reduced immune response activation,
and efficient cellular uptake. These hybrid oligonucleotide
molecules combine the beneficial properties of conventional RNAi
and antisense technologies. This allows sd‑rxRNAs to achieve
efficient cellular uptake and potent, long-lasting intracellular
activity.
About RXi Pharmaceuticals Corporation
RXi Pharmaceuticals Corporation (NASDAQ: RXII) is a
biotechnology company focused on discovering, developing and
commercializing innovative therapies based on its proprietary,
self-delivering RNAi platform. Therapeutics that use RNA
interference, or "RNAi," have great promise because of their
ability to down-regulate the expression of a specific gene that may
be over-expressed in a disease condition. Building on the
pioneering work of scientific founder and Nobel Laureate Dr.
Craig Mello, a member of the RXi
Scientific Advisory Board, RXi's first RNAi product candidate,
RXI‑109, targets connective tissue growth factor (CTGF) to reduce
dermal scarring (fibrosis), entered into human clinical trials in
June 2012. For more information, please visit
www.rxipharma.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. Such statements include, but are not limited to, statements
about future expectations, planned and future development of RXi
Pharmaceuticals Corporation's products and technologies.
Forward-looking statements about expectations and development plans
of RXi's products involve significant risks, and uncertainties:
risks that RXi may not be able to successfully develop its
candidates, or that development of RNAi-based therapeutics may be
delayed or not proceed as planned, or that we may not develop any
RNAi-based product; risks that the development process for our
product candidates may be delayed, risks related to development and
commercialization of products by our competitors, risks related to
our ability to control timing and terms of collaborations with
third parties, and the possibility that other companies or
organizations may assert patent rights preventing us from
developing our products. Actual results may differ from those
contemplated by these forward-looking statements. RXi does not
undertake to update forward-looking statements to reflect a change
in its views, events or circumstances that occur after the date of
this release.
Contacts
RXi Pharmaceuticals Corporation
Tamara McGrillen, 508-929-3646
tmcgrillen@rxipharma.com
Logo -
http://photos.prnewswire.com/prnh/20130917/NE80755LOGO
SOURCE RXi Pharmaceuticals Corporation